SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs ...
Q3 2025 Earnings Call Transcript November 6, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-0.51282, expectations were $-2.15. Operator: Good day, and thank you for standing by.
Get the latest insights from Moderna's Q3 2025 earnings call: revenue guidance updates, cost reduction highlights, and pipeline progress.
The controlled multi-centre, randomised, prospective trial is investigating the therapy in kidney transplant recipients.
Viral infections, including HIV and influenza, are associated with an increased risk of cardiovascular disease, including coronary heart disease and stroke.
The study, titled “ Strategic Help with Immunoglobulin to Enhance protection against Late Disease (CMV) ” or SHIELD, is a prospective, randomized, controlled multicenter investigator-initiated study ...
A comprehensive eight-year study examining audiological outcomes of newborns screened for congenital cytomegalovirus (cCMV) ...
Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus vaccine candidate, mRNA-1647.
CMV is particularly linked to immune remodeling, including the expansion of highly differentiated CD8⁺ T cells (Tem, Temra), ...
CAMBRIDGE, MA / ACCESS Newswire / October 22, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the Company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback